Journament

Keyword Connections - sars-cov-2 Keywords

Connection Type	Connection
Journals	PloS one Journal of medical Internet research Asian journal of psychiatry mmwr morbidity and mortality weekly report anaesthesiology intensive therapy medwave acta bio-medica : atenei parmensis swiss medical weekly
Research Groups	No Research Group Connected
Bibliographies	[1] COVID-19 - what should anaethesiologists and intensivists know about it? [2] COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. [3] Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. [4] Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore - January 2-February 29, 2020. [5] Initial Investigation of Transmission of COVID-19 Among Crew Members During Quarantine of a Cruise Ship - Yokohama, Japan, February 2020. [6] Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? [7] WHO Declares COVID-19 a Pandemic. [8] Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature. [9] Containing COVID-19 among 627,386 Persons Contacting with Diamond Princess Cruise Ship Passengers Disembarked in Taiwan: Big Data Analytics. [10] Keeping the country positive during the COVID 19 pandemic: Evidence from India. [11] Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters [12] Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [13] COVID-19: combining antiviral and anti-inflammatory treatments [14] Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial [15] Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China [16] Impact of COVID-19 on people with cystic fibrosis [17] Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis [18] Low incidence of COVID-19 in children and adolescent post-liver transplant at a Latin American reference center [19] The COVID-19 Pandemic from an Ophthalmologist's Perspective [20] The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients [21] A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features [22] COVID-19 and Nasal Cytobrush Cytology [23] Smell and taste dysfunction in patients with COVID-19 [24] Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies [25] Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis [26] In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [27] Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy [28] Hydroxychloroquine prophylaxis for COVID-19 contacts in India [29] Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment [30] Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure [31] A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [32] COVID-19 versus SARS: A comparative review [33] A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS [34] Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020 [35] Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. [36] Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? [37] A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview. [38] Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak [39] The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines [40] Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? [41] Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy. [42] Response to: Sore throat in COVID-19: comment on "Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis". [43] Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Integrated Computational Approach. [44] Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids. [45] Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. [46] F-FDG uptake in Asymptomatic SARS-CoV-2 (COVID-19) patient, referred to PET/CT for Non-Small Cells Lung Cancer restaging. [47] Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians [48] The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation? [49] The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. [50] Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [51] Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection. [52] Nuclear medicine in SARS-CoV-2 pandemia: 18F-FDG-PET/CT to visualize COVID-19. [53] Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. [54] Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. [55] Stability and Viability of SARS-CoV-2. Reply. [56] Stability and Viability of SARS-CoV-2. [57] Stability and Viability of SARS-CoV-2. [58] Stability and Viability of SARS-CoV-2. [59] Stability and Viability of SARS-CoV-2. [60] Stability and Viability of SARS-CoV-2. [61] A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran. [62] Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense. [63] Clinical Trials during the SARS-CoV-2 Pandemic. [64] The evidence of SARS-CoV-2 infection on ocular surface. [65] [Obstetric Anesthesia During the SARS-CoV-2 Pandemic - a Brief Overview of Published Recommendations for Action by National and International Specialist Societies and Committees]. [66] Supporting pandemic response using genomics and bioinformatics: a case study on the emergent SARS-CoV-2 outbreak. [67] Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? [68] Advanced forecasting of SARS-CoV-2 related deaths in Italy, Germany, Spain, and New York State. [69] Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. [70] Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [71] Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. [72] The Architecture of SARS-CoV-2 Transcriptome. [73] What do we know about the SARS-CoV-2 coronavirus in the environment? [74] Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient [75] Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2. [76] A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. [77] Occupational exposure to SARS-CoV-2 in burns treatment during the COVID-19 epidemic: Specific diagnosis and treatment protocol. [78] Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2. [79] Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories [80] The Malnutritional Status of the Host as a Virulence Factor for New Coronavirus SARS-CoV-2 [81] Properties of Coronavirus and SARS-CoV-2. [82] Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity). [83] Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. [84] Treatment of SARS-CoV-2: How far have we reached? [85] Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. [86] Perspective: SARS-CoV-2, COVID-19 and Haematologists. [87] Structure-based Virtual Screening and Molecular Dynamic Simulation Studies of the Natural Inhibitors of SARS-CoV-2 Main Protease [88] Delivery in pregnant women infected with SARS-CoV-2: A fast review. [89] Validation of SARS-CoV-2 detection across multiple specimen types. [90] A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). [91] Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence? [92] Electron microscopy of SARS-CoV-2: a challenging task. [93] Electron microscopy of SARS-CoV-2: a challenging task - Authors' reply. [94] Tale of three seeding patterns of SARS-CoV-2 in Saudi Arabia. [95] Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection (Nature Communications, (2020), 11, 1, (2251), 10.1038/s41467-020-16256-y) [96] Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome [97] Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M<sup>pro</sup> [98] COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms [99] A human monoclonal antibody blocking SARS-CoV-2 infection [100] The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro [101] Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction